Caris Life Sciences (NASDAQ:CAI) Shares Down 9.8% – What’s Next?
by Jessica Moore · The Cerbat GemCaris Life Sciences, Inc. (NASDAQ:CAI – Get Free Report) shares fell 9.8% on Monday . The company traded as low as $25.30 and last traded at $25.73. 1,122,601 shares traded hands during trading, a decline of 50% from the average session volume of 2,253,037 shares. The stock had previously closed at $28.51.
Wall Street Analysts Forecast Growth
CAI has been the topic of several recent analyst reports. Wall Street Zen cut shares of Caris Life Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, December 6th. Canaccord Genuity Group boosted their price target on shares of Caris Life Sciences from $28.00 to $30.00 and gave the stock a “hold” rating in a report on Monday, December 22nd. Evercore ISI set a $38.00 price objective on shares of Caris Life Sciences in a research report on Monday, January 5th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Caris Life Sciences in a research report on Monday, December 29th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $34.00.
Read Our Latest Research Report on CAI
Caris Life Sciences Price Performance
The stock has a market cap of $7.45 billion and a PE ratio of -57.43. The company has a current ratio of 9.93, a quick ratio of 9.36 and a debt-to-equity ratio of 0.79.
Insider Transactions at Caris Life Sciences
In other Caris Life Sciences news, insider Luke Thomas Power sold 62,250 shares of Caris Life Sciences stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $26.58, for a total transaction of $1,654,605.00. Following the completion of the transaction, the insider owned 99,571 shares of the company’s stock, valued at $2,646,597.18. The trade was a 38.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 7.80% of the company’s stock.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Caris Life Sciences stock. Olistico Wealth LLC bought a new stake in Caris Life Sciences, Inc. (NASDAQ:CAI – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,152 shares of the company’s stock, valued at approximately $31,000.
About Caris Life Sciences
Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.
Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.